Literature DB >> 28680307

Thyroid Function and Ultrasonography Abnormalities in Lithium-Treated Bipolar Patients: A Cross-sectional Study with Healthy Controls.

Özlem Kuman Tunçel1, Fisun Akdeniz2, Süha Süreyya Özbek3, Gülgün Kavukçu3, Gökçen Ünal Kocabaş4.   

Abstract

INTRODUCTION: Lithium has many effects on thyroid physiology. Although these side effects have been known for a long time, large sample studies of lithium-treated patients using ultrasonography are lacking. The aim of this study is to investigate the detailed thyroid morphologies, hormone levels, and antibodies of lithium-treated patients compared with healthy controls.
METHODS: This cross-sectional study involved 84 lithium-treated patients with bipolar disorder and 65 gender and age similar controls who had never been exposed to lithium. Subjects between 18 and 65 years of age were eligible for the study. Venous blood samples were acquired to determine the levels of free thyroxine (fT4), thyroid stimulating hormone (TSH), and thyroid antibodies; also, ultrasonographic examinations of the patients' thyroid glands were performed.
RESULTS: There were no statistically significant differences in smoking habits, known thyroid disease, thyroid medication use, familial thyroid disease, fT4 level, autoimmunity, thyroid nodule presence, or Hashimoto's thyroiditis between the lithium and control groups. The median TSH level and thyroid volume were significantly higher in the lithium group. In the lithium group, 14 cases (16.7%) of hypothyroidism, seven cases (8.3%) of subclinical hypothyroidism, and one case (1.2%) of subclinical hyperthyroidism were defined; in the control group, seven cases (10.8%) of hypothyroidism and two cases (3.1%) of subclinical hyperthyroidism were defined. Thyroid dysfunction, goiter, parenchymal abnormality, ultrasonographically defined thyroid abnormality, and thyroid disorder were found to be more prevalent in the lithium group. 90% of patients with goiter and 74.3% of patients with ultrasonographic pathologies were euthyroid.
CONCLUSION: It is important to note that 90% of the patients with goiter were euthyroid. This indicates that monitoring by blood test alone is insufficient. The prevalence rates of 47.6% for goiter and 83.3% for ultrasonographic pathology demonstrate that ultasonographic follow-up may be useful in lithium-treated patients. To determine whether routine ultrasonographic examination is necessary, large sample prospective studies are necessary due to the limitations of this study.

Entities:  

Keywords:  Goiter; hypothyroidism; lithium; thyroid gland; ultrasonography

Year:  2017        PMID: 28680307      PMCID: PMC5491659          DOI: 10.5152/npa.2017.12457

Source DB:  PubMed          Journal:  Noro Psikiyatr Ars        ISSN: 1300-0667            Impact factor:   1.339


  47 in total

1.  Validation of ultrasonography of the thyroid gland for epidemiological purposes.

Authors:  N Knudsen; B Bols; I Bülow; T Jørgensen; H Perrild; L Ovesen; P Laurberg
Journal:  Thyroid       Date:  1999-11       Impact factor: 6.568

2.  Six-year follow-up of thyroid function during lithium treatment.

Authors:  A Bocchetta; A Cherchi; A Loviselli; P Mossa; F Velluzzi; R Derai; M Del Zompo
Journal:  Acta Psychiatr Scand       Date:  1996-07       Impact factor: 6.392

3.  Possible hypothyroidism associated with quetiapine.

Authors:  B M Feret; C F Caley
Journal:  Ann Pharmacother       Date:  2000-04       Impact factor: 3.154

Review 4.  Lithium: a review of its metabolic adverse effects.

Authors:  Callum Livingstone; Hagan Rampes
Journal:  J Psychopharmacol       Date:  2005-09-20       Impact factor: 4.153

5.  Value of thyroid echography in the long-term follow-up of lithium-treated patients.

Authors:  A Loviselli; A Bocchetta; P Mossa; F Velluzzi; F Bernardi; M del Zompo; S Mariotti
Journal:  Neuropsychobiology       Date:  1997       Impact factor: 2.328

6.  Thyroid abnormalities in lithium-treated patients with bipolar affective disorder.

Authors:  A Cayköylü; I Capoğlu; N Unüvar; F Erdem; R Cetinkaya
Journal:  J Int Med Res       Date:  2002 Jan-Feb       Impact factor: 1.671

7.  Thyroid disorders in lithium-treated patients.

Authors:  G Kirov
Journal:  J Affect Disord       Date:  1998-07       Impact factor: 4.839

8.  Renal, thyroid and parathyroid function during lithium treatment: laboratory tests in 207 people treated for 1-30 years.

Authors:  G Kallner; U Petterson
Journal:  Acta Psychiatr Scand       Date:  1995-01       Impact factor: 6.392

9.  Using ultrasonography to determine thyroid size and prevalence of goiter in lithium-treated patients with affective disorders.

Authors:  Michael Bauer; Holger Blumentritt; Reinhard Finke; Peter Schlattmann; Mazda Adli; Christopher Baethge; Tom Bschor; Bruno Müller-Oerlinghausen; Anne Berghöfer
Journal:  J Affect Disord       Date:  2007-03-07       Impact factor: 4.839

10.  A cross-sectional and a prospective study of thyroid disorders in lithium-treated patients.

Authors:  George Kirov; John Tredget; Rhys John; Michael J Owen; John H Lazarus
Journal:  J Affect Disord       Date:  2005-08       Impact factor: 4.839

View more
  4 in total

Review 1.  The Role of Lithium in Management of Endocrine Tumors-A Comprehensive Review.

Authors:  Shilpa Thakur; Andrew Tobey; Joanna Klubo-Gwiezdzinska
Journal:  Front Oncol       Date:  2019-10-18       Impact factor: 6.244

2.  Comparison of thyroid function in different emotional states of drug-naïve patients with bipolar disorder.

Authors:  Shengnan Zhao; Xu Zhang; Yaling Zhou; Hao Xu; Yuwei Li; Yuexin Chen; Bo Zhang; Xueli Sun
Journal:  BMC Endocr Disord       Date:  2021-10-21       Impact factor: 2.763

3.  An Adolescent Female with Bipolar Disorder Presenting with Lithium-Induced Hyperthyroidism.

Authors:  Pratibha Rana; Patria Alba Aponte; Ghufran Babar
Journal:  Case Rep Endocrinol       Date:  2020-02-12

4.  Lithium-associated hypothyroidism and potential for reversibility after lithium discontinuation: Findings from the LiSIE retrospective cohort study.

Authors:  Ingrid Lieber; Michael Ott; Louise Öhlund; Robert Lundqvist; Mats Eliasson; Mikael Sandlund; Ursula Werneke
Journal:  J Psychopharmacol       Date:  2019-10-31       Impact factor: 4.153

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.